Drugs Made In America Acquisition II Corp.
DMIIU- Exchange
- Nasdaq
- Industry
- Blank Checks
- SEC CIK
- 0002040475
No open-market purchases or sales by Drugs Made In America Acquisition II Corp. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $35.0M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Drugs Made In America Acquisition II Corp. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Drugs Made In America Acquisition II Corp., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Do Catherine | Director | 100,000 | Oct 17, 2025 | 1 |
| Shulgan Myron W. | Director | 100,000 | Oct 2, 2025 | 1 |
| Worman Glenn C. | CFO | 100,000 | Oct 1, 2025 | 1 |
| Stockwell Lynn | CEO and Exe. Chair of Board | 6,708,333Indirect | Oct 1, 2025 | 1 |
| Prasad Sridhar G. | Director | 100,000 | Oct 1, 2025 | 1 |
| Drugs Made In America Acquisition II LLC | 10% Owner | 6,708,333 | Oct 1, 2025 | 1 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Stockwell LynnCEO and Exe. Chair of Board | PPurchase | +700.0K | – | – | +4.9%15.1M after | Duplicate filing |
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Stockwell LynnCEO and Exe. Chair of Board | SSale | −7.97M | – | – | −54.3%6.71M after | Duplicate filing |
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Stockwell LynnCEO and Exe. Chair of Board | PPurchase | +70.0K | – | – | –700.0K after | Derivative |
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Drugs Made In America Acquisition II LLC10% Owner | PPurchase | +700.0K | – | – | +4.9%15.1M after | |
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Drugs Made In America Acquisition II LLC10% Owner | SSale | −7.97M | – | – | −54.3%6.71M after | |
| Oct 1, 2025 (view filing) | Sep 26 | 5 daysLate | Drugs Made In America Acquisition II LLC10% Owner | PPurchase | +700.0K | – | – | –700.0K after | Derivative |